Ceftolozane/Tazobactam Activity Against Drug-Resistant
Asia
Enterobacterales
P. aeruginosa
ceftolozane/tazobactam
drug resistance
surveillance
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
08
2022
accepted:
14
11
2022
entrez:
29
11
2022
pubmed:
30
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
To evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against A total of 2038 Gram-negative organisms (376 Ceftolozane/tazobactam was the most potent (MIC Ceftolozane/tazobactam was the most active β-lactam agent tested against
Identifiants
pubmed: 36444213
doi: 10.2147/IDR.S387097
pii: 387097
pmc: PMC9700433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6739-6753Informations de copyright
© 2022 Pfaller et al.
Déclaration de conflit d'intérêts
W-T Chen is an employee of Merck & Co., Inc., Kenilworth, NJ, USA. MP, DS, HS and MC are affiliated with JMI Laboratories. The authors report no other conflicts of interest in this work.
Références
Antimicrob Agents Chemother. 2013 Dec;57(12):6305-10
pubmed: 24100499
Clin Infect Dis. 2020 Dec 3;71(9):e523-e529
pubmed: 32052041
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8
pubmed: 23535208
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183
pubmed: 33106864
Int J Antimicrob Agents. 2002 Jul;20(1):10-7
pubmed: 12127706
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Antimicrob Agents Chemother. 2013 Jul;57(7):2981-8
pubmed: 23587958
Clin Ther. 2012 Jan;34(1):124-37
pubmed: 22154196
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S23-S33
pubmed: 30895212
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0231820
pubmed: 33875428
Int J Antimicrob Agents. 2014 Jun;43(6):533-9
pubmed: 24856078
Infect Control Hosp Epidemiol. 2020 Jan;41(1):1-18
pubmed: 31767041
J Infect. 2010 Jun;60(6):440-51
pubmed: 20361999
N Engl J Med. 2020 Apr 2;382(14):1309-1319
pubmed: 32242356
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
pubmed: 16355321
Antimicrob Resist Infect Control. 2021 Apr 8;10(1):68
pubmed: 33832545
Trop Med Int Health. 2011 Sep;16(9):1167-79
pubmed: 21707879
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S1-S4
pubmed: 30895209
Int J Antimicrob Agents. 2011 Apr;37(4):291-5
pubmed: 21382699
Int J Antimicrob Agents. 2018 Feb;51(2):181-189
pubmed: 28993143
Diagn Microbiol Infect Dis. 2005 Aug;52(4):323-9
pubmed: 16165001
J Antimicrob Chemother. 2014 Oct;69(10):2713-22
pubmed: 24917579
J Infect. 2011 Apr;62(4):280-91
pubmed: 21382411
Crit Care Med. 2015 Oct;43(10):2133-40
pubmed: 26121071
Clin Infect Dis. 2021 May 18;72(10):1784-1792
pubmed: 32519751
Clin Infect Dis. 2017 Jul 1;65(1):158-161
pubmed: 28329350
Diagn Microbiol Infect Dis. 2002 Mar;42(3):193-8
pubmed: 11929691
J Infect. 2014 Sep;69(3):266-77
pubmed: 24780763
Clin Infect Dis. 2011 Sep;53 Suppl 2:S33-55; quiz S56-8
pubmed: 21868447
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S63-S68
pubmed: 30895216